12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aripiprazole depot regulatory update

Otsuka and partner Lundbeck said FDA accepted for review a resubmitted NDA for a once-monthly depot formulation of aripiprazole for the maintenance treatment of schizophrenia. The agency designated the application as a class 2 resubmission, with...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >